Premium
Recovery from Marie‐Bamberger's syndrome and diabetes insipidus after removal of a lung adenocarcinoma with neuroendocrine features
Author(s) -
Magdy ElSalhy,
Magnus Simonsson,
Roger Stenling,
Lars Grimelius
Publication year - 1998
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1046/j.1365-2796.1998.00262.x
Subject(s) - medicine , diabetes insipidus , endocrinology , adenocarcinoma , lung , diabetes mellitus , cancer
El‐Salhy M, Simonsson M, Stenling R, Grimelius L (University Hospital, Umeå; and University Hospital, Uppsala; Sweden). Recovery from Marie‐Bamberger's syndrome and diabetes insipidus after removal of a lung adenocarcinoma with neuroendocrine features (Case Report). J Intern Med 1998; 243 : 171–75 A 44‐year‐old woman with Marie‐Bamberger's syndrome and diabetes insipidus had a lung tumour with mediastinal metastases, but no signs of metastases to the hypothalamus or pituitary gland. A week after removal of the tumour, the joint pain, polyuria and polydipsia disappeared. The tumour was diagnosed histopathologically as a moderately differentiated adenocarcinoma with focal neuroendocrine cell differentiation and dispersed cells reacting with antisera against neurone‐specific enolase, S‐100 protein, neuropeptide Y, follicle‐stimulating hormone, substance P, vasoactive polypeptide (VIP), adrenocortirotropic hormone and pancreatic polypeptide (PP) as well as to one of three tested antisera raised against antidiuretic hormone (ADH). It was suggested that Marie‐Bamberger's syndrome might be caused by one of these immunoreactive substances or by a substance that shares an amino acid sequence with one of these neuroendocrine peptides. It was also suggested that the tumour might produce an ADH‐like substance which might have an ADH‐antagonist effect.